Aggressive non-Hodgkin's lymphomas (NHL) in localized stages I and II, without bulky areas
and a fair International Prognostic Factor (IPI)(30% of all cases) have high possibilities of …

The Groupe d'Etude des Lymphomes de l'Adulte (GELA) has conducted several phase II
and III studies in patients with aggressive lymphoma, diffuse large B-cell lymphoma …

Although radiotherapy was considered sufficient for stage I and limited stage II aggressive
non-Hodgkin's lymphoma in the past, new data from randomized studies have shown that …

Aim of the study was to improve cure rate and survival of aggressive non-Hodgkin's
lymphoma (NHL) with a tailored program of therapy based on histologic type, prognostic …

Abstract From July 1971 to August 1975, 63 previously untreated patients with stage IV non-
Hodgkin's lymphomas with favorable histologies were prospectively randomized to three …

In an unselected group of patients with aggressive non-Hodgkin's lymphoma (A-NHL)
treated at our institution during a 10-year period (1989–1998), we studied the treatment …

In the past, CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
was considered the gold standard treatment for aggressive non-Hodgkin's lymphoma (NHL) …

Histological diagnosis according to WHO classification and determination of usual
prognostic factors are necessary to choose between treatment options in non-Hodgkin …

Therapy for aggressive non‐Hodgkin's lymphomas has undergone significant evolution in
the last 25 years. First generation combination chemotherapy studies produced complete …

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of disorders which can either
be classified according to their biology, represented by corresponding counterparts of …